Centrexion Therapeutics is notable for focusing solely on developing non-opioid, non-addictive pain drugs-an area that biopharma companies have largely avoided. Now the Boston-based startup wants Wall Street’s help with the effort.
Centrexion has outlined plans for an IPO. The company has set a preliminary IPO target of $86 million, though that figure is subject to change as the offering gets closer. Should Centrexion close its IPO, it will list on the Nasdaq under the symbol CNTX.
Centrexion, headed by former Pfizer CEO Jeff Kindler, is testing its lead drug, CNTX-4975, in two Phase 3 clinical trials for pain… Read more »
UNDERWRITERS AND PARTNERS